These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 27933954)

  • 1. Discovery of [5-Amino-1-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(1H-indol-2-yl)methanone (CH5183284/Debio 1347), An Orally Available and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor.
    Ebiike H; Taka N; Matsushita M; Ohmori M; Takami K; Hyohdoh I; Kohchi M; Hayase T; Nishii H; Morikami K; Nakanishi Y; Akiyama N; Shindoh H; Ishii N; Isobe T; Matsuoka H
    J Med Chem; 2016 Dec; 59(23):10586-10600. PubMed ID: 27933954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.
    Nakanishi Y; Akiyama N; Tsukaguchi T; Fujii T; Sakata K; Sase H; Isobe T; Morikami K; Shindoh H; Mio T; Ebiike H; Taka N; Aoki Y; Ishii N
    Mol Cancer Ther; 2014 Nov; 13(11):2547-58. PubMed ID: 25169980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 3-(5'-Substituted)-Benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors: Design, Synthesis, and Biological Evaluation.
    Yan W; Wang X; Dai Y; Zhao B; Yang X; Fan J; Gao Y; Meng F; Wang Y; Luo C; Ai J; Geng M; Duan W
    J Med Chem; 2016 Jul; 59(14):6690-708. PubMed ID: 27348537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
    Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
    Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.
    Velaparthi U; Wittman M; Liu P; Carboni JM; Lee FY; Attar R; Balimane P; Clarke W; Sinz MW; Hurlburt W; Patel K; Discenza L; Kim S; Gottardis M; Greer A; Li A; Saulnier M; Yang Z; Zimmermann K; Trainor G; Vyas D
    J Med Chem; 2008 Oct; 51(19):5897-900. PubMed ID: 18763755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.
    Nakanishi Y; Mizuno H; Sase H; Fujii T; Sakata K; Akiyama N; Aoki Y; Aoki M; Ishii N
    Mol Cancer Ther; 2015 Dec; 14(12):2831-9. PubMed ID: 26438159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models.
    Zhao G; Li WY; Chen D; Henry JR; Li HY; Chen Z; Zia-Ebrahimi M; Bloem L; Zhai Y; Huss K; Peng SB; McCann DJ
    Mol Cancer Ther; 2011 Nov; 10(11):2200-10. PubMed ID: 21900693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.
    Perera TPS; Jovcheva E; Mevellec L; Vialard J; De Lange D; Verhulst T; Paulussen C; Van De Ven K; King P; Freyne E; Rees DC; Squires M; Saxty G; Page M; Murray CW; Gilissen R; Ward G; Thompson NT; Newell DR; Cheng N; Xie L; Yang J; Platero SJ; Karkera JD; Moy C; Angibaud P; Laquerre S; Lorenzi MV
    Mol Cancer Ther; 2017 Jun; 16(6):1010-1020. PubMed ID: 28341788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.
    Gavine PR; Mooney L; Kilgour E; Thomas AP; Al-Kadhimi K; Beck S; Rooney C; Coleman T; Baker D; Mellor MJ; Brooks AN; Klinowska T
    Cancer Res; 2012 Apr; 72(8):2045-56. PubMed ID: 22369928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and Optimization of a Novel 2
    Wei Y; Tang Y; Zhou Y; Yang Y; Cui Y; Wang X; Wang Y; Liu Y; Liu N; Wang Q; Li C; Ruan H; Zhou H; Wei M; Yang G; Yang C
    J Med Chem; 2021 Jul; 64(13):9078-9099. PubMed ID: 34129329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
    André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
    Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy.
    Kong B; Zhu Z; Li H; Hong Q; Wang C; Ma Y; Zheng W; Jiang F; Zhang Z; Ran T; Bian Y; Yang N; Lu T; Zhu J; Tang W; Chen Y
    Eur J Med Chem; 2022 Jan; 227():113953. PubMed ID: 34731760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and biological evaluation of 5-amino-1H-pyrazole-4-carboxamide derivatives as pan-FGFR covalent inhibitors.
    Deng W; Chen X; Liang H; Song X; Xiang S; Guo J; Tu Z; Zhou Y; Chen Y; Lu X
    Eur J Med Chem; 2024 Sep; 275():116558. PubMed ID: 38870833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives as potent fibroblast growth factor receptor (FGFR) inhibitors.
    Wei M; Peng X; Xing L; Dai Y; Huang R; Geng M; Zhang A; Ai J; Song Z
    Eur J Med Chem; 2018 Jun; 154():9-28. PubMed ID: 29775937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers.
    Lelais G; Epple R; Marsilje TH; Long YO; McNeill M; Chen B; Lu W; Anumolu J; Badiger S; Bursulaya B; DiDonato M; Fong R; Juarez J; Li J; Manuia M; Mason DE; Gordon P; Groessl T; Johnson K; Jia Y; Kasibhatla S; Li C; Isbell J; Spraggon G; Bender S; Michellys PY
    J Med Chem; 2016 Jul; 59(14):6671-89. PubMed ID: 27433829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and identification of a selective FGFR2 degrader with potent antiproliferative effects in gastric cancer.
    Feng Z; Wang S; Yu S; Qu C; Chu B; Qian Z
    Eur J Med Chem; 2024 Nov; 277():116780. PubMed ID: 39167894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.
    Watanabe Miyano S; Yamamoto Y; Kodama K; Miyajima Y; Mikamoto M; Nakagawa T; Kuramochi H; Funasaka S; Nagao S; Sugi NH; Okamoto K; Minoshima Y; Nakatani Y; Karoji Y; Ohashi I; Yamane Y; Okada T; Matsushima T; Matsui J; Iwata M; Uenaka T; Tsuruoka A
    Mol Cancer Ther; 2016 Nov; 15(11):2630-2639. PubMed ID: 27535969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of N-(4-((6-(3,5- Dimethoxyphenyl)-9H-purine derivatives as irreversible covalent FGFR inhibitors.
    Wang Y; Pan Y; Lv Z; Gou S
    Eur J Med Chem; 2024 May; 271():116415. PubMed ID: 38643670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.
    Guagnano V; Furet P; Spanka C; Bordas V; Le Douget M; Stamm C; Brueggen J; Jensen MR; Schnell C; Schmid H; Wartmann M; Berghausen J; Drueckes P; Zimmerlin A; Bussiere D; Murray J; Graus Porta D
    J Med Chem; 2011 Oct; 54(20):7066-83. PubMed ID: 21936542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and biological evaluation of pyrazolylaminoquinazoline derivatives as highly potent pan-fibroblast growth factor receptor inhibitors.
    Fan J; Dai Y; Shao J; Peng X; Wang C; Cao S; Zhao B; Ai J; Geng M; Duan W
    Bioorg Med Chem Lett; 2016 Jun; 26(11):2594-9. PubMed ID: 27117427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.